Table 4.

Selected clinical studies in lichen planus.

Study	Lichen planus	Intervention	Target	Design	Phase	Status
NCT03697460	Cutaneous LP	INCB018424 (Ruxolitinib)	JAK1/2	Single center, exploratory, open-label, single-arm	2	Completed (2021)
NCT03656666	Genital erosive LP	Apremilast	PDE4	Double-blinded, randomized, placebo-controlled	2	Recruiting (2021)
NCT05030415	Lichen planopilaris and LP	Ixekizumab	IL17A	Open-label		Recruiting (2021)
NCT04300296	Lichen planopilaris, oral and cutaneous LP	Secukinumab	IL17A	Multicenter, randomized, double-blind, placebo-controlled	2	Active, not recruiting (2021)
NCT03417141	Lichen planopilaris	Mechlorethamin (Valchlor)	–	Open-label	2	Completed (2021)
NCT04409041	Lichen planopilaris and frontal fibrosing alopecia	Naltrexone	Opiate-receptor	Open-label	2	Completed (2021)
NCT03858634	Pruritus, CIU, LP, Lichen simplex chronicus, plaque psoriasis	Vixarelimab (KPL-716)	Oncostatin M receptor beta	Quadruple -blinded, randomized	2	Completed (2020)
NCT04976673	Oral LP	PDT	–	Double-blinded, randomized	2	Completed (2021)
NCT01282515	Female genital erosive LP	PDT	–	Single (investigator)-blinded, randomized	2/3	Completed (2021)
NCT04991012	Oral LP	PDT	–	Double-blinded, randomized	2	Completed (2021)

A search on clinicaltrials.gov was conducted on September 25th, 2021 with the key word “lichen planus”. A total of 116 clinical studies were identified. We focused on studies with a molecular target. A total of 14 completed interventional studies with molecular targets were updated since 2020. In addition, 2 studies with a defined molecular target (status: not recruiting/recruiting, enrolling by invitation/active, not recruiting) were found. We also included completed (with updates since 2020) and ongoing studies using photodynamic therapy. Number in brackets in the Status column indicate the last year, the study was updated in clincaltrials.gov. CIU, Chronic idiopathic urticarial; LP, Lichen planus; PDT, Photodynamic therapy.